Recurrent Breast Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00733408Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerTreatment
NCT00017394Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast CancerTreatment
NCT00055861Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast CancerTreatment